))
Receptor Occupancy Testing in Clinical Trials
Manage episode 442681453 series 3604305
Content provided by KCAS. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by KCAS or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
For episode #8 of “The Conversational Flow” podcast, Brian and Adam spend the time discussing Receptor Occupancy Testing in Clinical Trials. Receptor occupancy (RO) assays are important in clinical trials because they provide valuable information about a drug’s binding characteristics and mechanism of action. Our hosts begin by outlining the general need for accurate RO calculation (per time point, per subject, etc), then they move on to pre-analytical risks (collection, shipment, transit, receipt, etc) and more specifics like staining and preparation process, acquisition and data analysis, harmonization between multiple testing facilities, and interpreting RO data.
“The Conversational Flow” an official podcast of KCAS Bio, and focuses on the more niche topic of Flow Cytometry and its role within the greater pharmaceutical, biopharmaceutical and bioanalytical industries. Every month, KCAS Bio will bring you another 60 minutes (or so) of friendly banter between our two finest Flow Cytometry experts as they chat over coffee and discuss what they’ve learned about the world of Flow Cytometry the past couple of weeks. “The Conversational Flow” is brought to you by KCAS Bio.
KCAS Bio is a progressive growing contract research organization of well over 250 talented and dedicated individuals with growing operations in Kansas City, Doylestown, PA, and Lyon, France, where we are committed to serving our clients and improving health worldwide. Our experienced scientists provide stand-alone bioanalytical services to the pharmaceutical, biopharmaceutical, animal health and medical device industries.
19 episodes
Share
